Systematic review and meta-analysis of the prognostic value of CXCR2 in solid tumor patients

Yong Yang; Baoyang Luo; Yong An; Han Sun; Huihua Cai; Donglin Sun

doi:10.18632/oncotarget.22285

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Meta-Analysis:

Systematic review and meta-analysis of the prognostic value of CXCR2 in solid tumor patients

Yong Yang, Baoyang Luo, Yong An, Han Sun, Huihua Cai and Donglin Sun _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:109740-109751. https://doi.org/10.18632/oncotarget.22285

Metrics: PDF 1034 views | HTML 1654 views | ?

Abstract

Yong Yang1,*, Baoyang Luo1,*, Yong An1, Han Sun2, Huihua Cai1 and Donglin Sun1

1Department of Hepatobiliary Pancreatic Surgery, The Third Affiliated Hospital of Soochow University, Changzhou 213003, People’s Republic of China

2Department of Orthopedic Surgery, The Third Affiliated Hospital of Soochow University, Changzhou 213003, People’s Republic of China

*These authors contributed equally to this work

Correspondence to:

Donglin Sun, email: [email protected]

Keywords: CXCR2, survival, solid tumor, biomarker, meta-analysis

Received: July 03, 2017 Accepted: October 02, 2017 Published: November 03, 2017

ABSTRACT

CXC chemokine receptor-2 (CXCR2) expression is associated with the prognosis of multiple cancers. We performed a meta-analysis to determine the association between the CXCR2 expression in tumor tissue and patient prognosis. We compiled related literature from PubMed, Embase, and Web of Science (last updated July 31, 2017). A total of 4012 patients with solid tumors from 21 studies were included to evaluate the association between CXCR2 and overall survival, recurrence-free survival, or disease-free survival. High CXCR2 expression was significantly associated with poor overall survival (pooled HR = 1.82; 95% CI = 1.63–2.03; P < 0.001), recurrence-free survival (pooled HR = 1.40; 95% CI = 1.21–1.62; P < 0.001), and disease-free survival (pooled HR = 1.89; 95% CI = 1.05–3.40; P = 0.033), especially in patients with digestive system neoplasms. Thus high CXCR2 expression in tumor tissue appears predictive of a poor prognosis in patients with solid tumors. Further studies will be required to determine whether CXCR2 blockade has a favorable effect on the prognosis of patients with cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22285

Publication Alerts

Meta-Analysis:

Systematic review and meta-analysis of the prognostic value of CXCR2 in solid tumor patients

Abstract